Eli Lilly Q2 revenue hits $23 billion, topping forecasts as tirzepatide drives two-thirds of sales
read at Endpoints ↗EarningsPositive
Eli Lilly reported second-quarter revenue of $23 billion, roughly $3 billion above analysts' estimates.
Tirzepatide contributed about 64% of the total, highlighting its central role in the company's sales mix.
The firm also lifted its full-year revenue outlook to a range of $85-87 billion.
The results underscore the continued market strength of GLP-1 therapies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly once again beats expectations as tirzepatide accounts for 64% of revenue”
read at Endpoints ↗80 words · retrieved Aug 5
comments(0)
5-min edit window · permanent after that